GlycoMimetics (GLYC) Misses Q3 EPS by 2c; Reports Cash and Cash Equivalents of $101.9
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021
November 2, 2021 7:30 AM EDTSignificant progress achieved for lead investigational drug candidate uproleselan: Robust enrollment momentum in the quarter indicates imminent completion of enrollment for Company-sponsored Phase 3 pivotal trial in patients with relapsed/refractory acute myeloid leukemia (AML); top line results anticipated after year-end 2022 Data showing high rate of Minimal Residual Disease (MRD) in evaluable relapsed/refractory AML patients were published in BLOOD, as part of a comprehensive review of the data set from the Companys Phase 1/2 trial evaluating uproleselan in both relapsed/refractory and newly diagnosed fit for chemo AML patient... More
